News archive for Brain tumour immunology and therapy group
Glioblastoma (GBM) is malignant brain tumor, where the best available treatment extends survival by approximately 15 months. The tumor has a diffusely infiltrative growth pattern and a microenvironment that makes it difficult to achieve a long-lasting treatment response. Understanding the mechanisms that lead to GBM treatment resistance is imperative for development of novel therapies.
- August 2024 (1)
- June 2024 (3)
- September 2023 (2)
- May 2023 (1)
- September 2021 (1)
- May 2021 (1)
- March 2021 (1)
- February 2021 (1)
- October 2020 (1)
- September 2019 (1)
- August 2019 (1)
- November 2018 (1)
- October 2018 (1)
- May 2018 (1)
- April 2018 (1)
- November 2017 (1)
- June 2014 (1)